Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Capital Expenditures (2020 - 2024)

HCW Biologics (HCWB) has disclosed Capital Expenditures for 5 consecutive years, with -$1.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Capital Expenditures fell 140.15% year-over-year to -$1.6 million, compared with a TTM value of -$1.6 million through Sep 2025, down 127.4%, and an annual FY2024 reading of $261617.0, down 95.78% over the prior year.
  • Capital Expenditures was -$1.6 million for Q4 2024 at HCW Biologics, down from $1.8 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $10.2 million in Q3 2022 and bottomed at -$10.2 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $391358.0, with a median of $36391.0 recorded in 2020.
  • Peak annual rise in Capital Expenditures hit 246909.7% in 2022, while the deepest fall reached 51512.66% in 2022.
  • Year by year, Capital Expenditures stood at $36391.0 in 2020, then plummeted by 45.45% to $19852.0 in 2021, then tumbled by 51512.66% to -$10.2 million in 2022, then surged by 140.24% to $4.1 million in 2023, then tumbled by 140.15% to -$1.6 million in 2024.
  • Business Quant data shows Capital Expenditures for HCWB at -$1.6 million in Q4 2024, $1.8 million in Q3 2024, and -$18567.0 in Q2 2024.